TradingMenu expanded
Forge Markets Browse Companies
DataMenu expanded
Forge Data IPO Stock Tracker
SolutionsMenu expanded
For Institutions For Shareholders For Investors For Companies In Europe
InsightsMenu expanded
All Insights Blog Reports Videos Webinars
Popular Topics
Buying Pre-IPO Shares Selling Pre-IPO Shares Private Market Reports Private Market Data & Analytics Startup News
AboutMenu expanded
About Us Team Investor Relations People & Culture Careers FAQs
Log In Sign Up
Trading Menu expandedTrading
Forge Markets
Browse Companies
Data Menu expandedData
Forge Data
IPO Stock Tracker
Solutions Menu expandedSolutions
For Institutions
For Shareholders
For Investors
For Companies
In Europe
Insights Menu expandedInsights
All Insights
Blog
Reports
Videos
Webinars
Popular Topics
Buying Pre-IPO Shares
Selling Pre-IPO Shares
Private Market Reports
Private Market Data & Analytics
Startup News
About Menu expandedAbout
About Us
Team
Investor Relations
People & Culture
Careers
FAQs
Trading / Browse Companies / SutroVax Stock

SutroVax Stock

sutrovax.comHealthcareFounded: 2013Funding to Date: $173.25MM

Developer of conjugate and novel complex antigen-based vaccines intended to prevent serious infectious diseases. The company's cell-free protein synthesis platform permits site-specific conjugation, enabling the creation of conjugate vaccines with the potential to deliver heightened immunity and broader protection.

Buy or sell SutroVax stockLearn more about SutroVax IPO
Register for Details

For more details on financing and valuation for SutroVax, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

OverviewFinancingsValuation

Enterprise Value (based on primary financings)

Powered by Forge Data
Enterprise Value

View Enterprise Value for SutroVax.

Register Today

Team

Management Team

Grant Pickering
Founder, President, Chief Executive Officer, Director & Board Member
Jeff Fairman Ph.D
Founder & Vice President of Research
Durga Bobba
Chief Business Officer
Elaine Sun
Chief Financial Officer
Aron Stein Ph.D
Vice President, Regulatory Affairs and Quality Assurance
Paul Sauer
Vice President, Process Development & Manufacturing

Board Members

Cristina Ghenoiu Ph.D
Longitude Capital
Moncef Slaoui Ph.D
Medicxi
Patrick Enright
Longitude Capital
Robert Hopfner Ph.D
NFLS - Pivotal
Francesco De Rubertis Ph.D
Medicxi
Kurt Von Emster
Abingworth Management
Nisha Marathe Ph.D
Roche Venture Fund
Peter Hirth Ph.D
Grant Pickering
Heath Lukatch Ph.D
Patrick Heron
Frazier Healthcare Partners
William Newell JD
Sutro Biopharma

Other companies like SutroVax in the Healthcare sector

Neuralink
Sector
Healthcare
Last Round Est. Valuation
$2.15B
Colossal Biosciences
Sector
Healthcare
 
 
Altos Labs
Sector
Healthcare
Last Round Est. Valuation
$3.67B
Synchron
Sector
Healthcare
Last Round Est. Valuation
$400.53MM
Grail
Sector
Healthcare
Last Round Est. Valuation
$4.26B
OURA
Sector
Healthcare
 
 
Mammoth Biosciences
Sector
Healthcare
Last Round Est. Valuation
$1.08B
Cytonics
Sector
Healthcare
 
 
Precision Neuroscience
Sector
Healthcare
 
 

News

FINSMES 03/26/2020
SutroVax Raises $110M in Series D Financing | FinSMEs
SutroVax, a Foster City, Calif.-based biopharmaceutical company dedicated to the delivery of novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide, closed a $110m Series D financing
FinSMEs 06/07/2018
SutroVax Raises $85M in Series C Financing |FinSMEs
SutroVax, a vaccine platform and development company, closed an $85m Series C financing. The round was led by TPG Growth, with participation from Medicxi and Foresite Capital and Abingworth, Longitude Capital, Frazier Health Care Partners, Pivotal bioVenture Partners, Roche Venture Fund, and CTI Life Sciences Fund
Market Screener 06/07/2018
SutroVax : Announces $85M Series C Financing led by TPG Growth

Trending Companies

Frequently Asked Questions